Cohort study of patients with chronic cardiovascular diseases

A Cohort Study of Chronic Cardiovascular Diseases in the Department of Cardiology, Peking University First Hospital

Peking University First Hospital · NCT04996342

This study looks at groups of people with long-term heart conditions to see how their treatments and health outcomes change over time.

Quick facts

Study typeObservational
Enrollment10000 (estimated)
Ages18 Years and up
SexAll
SponsorPeking University First Hospital (other)
Locations1 site (Beijing, 北京)
Trial IDNCT04996342 on ClinicalTrials.gov

What this trial studies

This observational cohort study aims to establish groups of patients suffering from various chronic cardiovascular diseases, including refractory hypertension, coronary heart disease, atrial fibrillation, and heart failure. It will collect data on patient characteristics, treatment status, and long-term prognosis to analyze factors influencing treatment choices and management quality. The study will involve long-term follow-up and regular visits to monitor the health outcomes of these patients.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with chronic cardiovascular conditions such as refractory hypertension, coronary heart disease, or atrial fibrillation who are willing to participate in long-term follow-up.

Not a fit: Patients with severe diseases of other systems that may affect their lifespan or those unable to commit to regular follow-up visits may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve understanding of chronic cardiovascular diseases and enhance treatment strategies for affected patients.

How similar studies have performed: Other studies focusing on chronic cardiovascular diseases have shown success in improving patient outcomes, indicating that this approach is supported by prior research.

Eligibility criteria

Show full inclusion / exclusion criteria
This study includes 9 disease-specific cohorts. The specific inclusion and exclusion criteria are as following:

1. Refractory and secondary hypertension

   Inclusion Criteria:
   * Patients diagnosed as refractory hypertension and/or secondary hypertension
   * Patients willing to accept long-term follow-up and regular return visits

   Exclusion Criteria:
   * Severe diseases of other systems may affecting the life span of patients
2. Coronary heart disease

   Inclusion Criteria:
   * Patients undergoing coronary angiography and interventional therapy in the cath lab
   * Patients undergoing coronary angiography and functional assessment in the cath lab
   * Patients diagnosed as acute myocardial infarction

   Exclusion Criteria:
   * Severe diseases of other systems may affecting the life span of patients
   * Regular return visits not available
3. Atrial fibrillation

   Inclusion Criteria:
   * PAtrial fibrillation diagnosed by electrocardiogram or holter (duration \>30 seconds)
   * Patients willing to accept long-term follow-up and regular return visits

   Exclusion Criteria:
   * Severe diseases of other systems may affecting the life span of patients
   * New-onset atrial fibrillation during the perioperative period of major surgery
4. Ventricular arrhythmias

   Inclusion Criteria:
   * Patients diagnosed as ventricular tachycardia, ventricular premature beat
   * Patients willing to accept long-term follow-up and regular return visits

   Exclusion Criteria:
   * Severe diseases of other systems may affecting the life span of patients
   * A transient cause of ventricular arrhythmia was determined by the doctor, and long-term follow-up was not required
5. Cardiac pacemaker implantation

   Inclusion Criteria:
   * Patients with permanent pacemaker implantations due to various causes (including bradycardia pacing, implantable cardioverter defibrillator, cardiac resynchronization therapy, leadless cardiac pacemaker, etc.)
   * Patients willing to accept long-term follow-up and regular return visits

   Exclusion Criteria:
   * Severe diseases of other systems may affecting the life span of patients
6. Structural heart disease

   Inclusion Criteria:
   * Patients diagnosed as structural heart disease, including congenital heart disease and severe valvular disease (moderate and above valvular stenosis or incomplete closure)
   * Patients willing to accept long-term follow-up and regular return visits

   Exclusion Criteria:
   * Severe diseases of other systems may affecting the life span of patients
7. Pulmonary hypertension

   Inclusion Criteria:
   * Patients diagnosed as pulmonary hypertension
   * Patients willing to accept long-term follow-up and regular return visits

   Exclusion Criteria:
   * Severe diseases of other systems may affecting the life span of patients
8. Heart failure

   Inclusion Criteria:
   * Patients diagnosed as heart failure
   * Patients willing to accept long-term follow-up and regular return visits

   Exclusion Criteria:
   * Severe diseases of other systems may affecting the life span of patients
9. Rare diseases of the cardiovascular system

Inclusion Criteria:

* Patients diagnosed as rare diseases in the catalog published by National Health Commission of the People's Republic of China
* Patients willing to accept long-term follow-up and regular return visits

Exclusion Criteria:

* Severe diseases of other systems may affecting the life span of patients

Where this trial is running

Beijing, 北京

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Cardiovascular Diseases, Cohort Studies

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.